Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation for acute myeloid leukemia

Andrew M Yeager, Georgia B. Vogelsang, Richard J. Jones, Evan R. Farmer, Allan D. Hess, George W. Santos

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Rodents given cyclosporhe (CSP) for several weeks after autologous or syngeneic bone marrow transplantation develop a syndrome that mimics allogeneic graft-versus-host disease (GVHD). Autologous GVHD has also been reported after administration of CSP in patients who have received autologous bone marrow transplantation (ABMT) with untreated marrow for lym-phoma or acute myeloid leukemia (AML). Our study was designed to determine whether CSP administration is associated with appearance of autologous GVHD in patients with AML receiving ABMT with 4-hydroperoxycyclophosphamide (4HC)-purged marrow and whether there was a dose-dependent effect of CSP on development of the syndrome. Thirty-three patients with AML (18 in first remission [CRl], 10 in CR2, and 5 in CR3) received intravenous CSP, beginning on the day of ABMT, after a preparative regimen of busulfan and cyclophosphamide and ABMT with 4HC-treated marrow. Skin biopsies were obtained weekly after ABMT or on appearance of rash and were graded for GVH changes. In the first phase of this study, groups of patients received CSP dosages of either 1 mg/kg/day (7 patients), 2.5 mg/kg/day (8 patients), or 3.75 mg/kg/day (6 patients) for 28 days. Sixteen of the 21 patients (76% developed cutaneous histopathologic grade 2 GVHD at a median of 34 days (range, 14-49) after ABMT, and cutaneous manifestations were present at time of positive biopsy in 11 of the 16 patients. There was no apparent difference in frequency, time to onset, or duration of GVHD among the three CSP dosage groups. In the subsequent trial, 12 patients received 1.0 mg/kg/day of CSP for 35 days; 6 developed biopsy-documented GVHD at a median of 42 days (range, 18-52) after ABMT. Overall, 22 of 33 patients (67% had positive biopsies for GVHD, compared with a historical 7% incidence of spontaneous GVHD in ABMT recipients. No patients had hepatic or gastrointestinal dysfunction attributable to GVHD or required specific therapy for GVHD. Six of the 33 patients died with ABMT-related complications; 3 had positive biopsies for cutaneous GVHD. Eleven patients (6 CR1, 4 CR2, 1 CR3) relapsed with AML at a median of 285 days (range, 115-633) after ABMT; 9 had positive biopsies. Sixteen patients (9 CRl, 3 CR2, 4 CR3) are alive without relapse at a median of 509+ days (range, 96+-1176+) after ABMT; 10 had cutaneous GVHD. Randomized prospective trials will be needed to determine whether autologous GVHD is associated with alterations in relapse rate and disease-free survival after ABMT for acute leukemia and lymphoma.

Original languageEnglish (US)
Pages (from-to)215-220
Number of pages6
JournalLeukemia and Lymphoma
Volume11
Issue number3-4
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Autologous Transplantation
Graft vs Host Disease
Bone Marrow Transplantation
Acute Myeloid Leukemia
Cyclosporine
perfosfamide
Biopsy
Skin
Bone Marrow
Isogeneic Transplantation
Skin Manifestations
Recurrence
Busulfan
Exanthema
Cyclophosphamide
Disease-Free Survival

Keywords

  • Acute myeloid leukemia
  • Autologous bone marrow transplantation
  • Cyclosporine
  • GVHD

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation for acute myeloid leukemia. / Yeager, Andrew M; Vogelsang, Georgia B.; Jones, Richard J.; Farmer, Evan R.; Hess, Allan D.; Santos, George W.

In: Leukemia and Lymphoma, Vol. 11, No. 3-4, 1993, p. 215-220.

Research output: Contribution to journalArticle

Yeager, Andrew M ; Vogelsang, Georgia B. ; Jones, Richard J. ; Farmer, Evan R. ; Hess, Allan D. ; Santos, George W. / Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation for acute myeloid leukemia. In: Leukemia and Lymphoma. 1993 ; Vol. 11, No. 3-4. pp. 215-220.
@article{8c96cc97d93a44598b9e810df9297279,
title = "Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation for acute myeloid leukemia",
abstract = "Rodents given cyclosporhe (CSP) for several weeks after autologous or syngeneic bone marrow transplantation develop a syndrome that mimics allogeneic graft-versus-host disease (GVHD). Autologous GVHD has also been reported after administration of CSP in patients who have received autologous bone marrow transplantation (ABMT) with untreated marrow for lym-phoma or acute myeloid leukemia (AML). Our study was designed to determine whether CSP administration is associated with appearance of autologous GVHD in patients with AML receiving ABMT with 4-hydroperoxycyclophosphamide (4HC)-purged marrow and whether there was a dose-dependent effect of CSP on development of the syndrome. Thirty-three patients with AML (18 in first remission [CRl], 10 in CR2, and 5 in CR3) received intravenous CSP, beginning on the day of ABMT, after a preparative regimen of busulfan and cyclophosphamide and ABMT with 4HC-treated marrow. Skin biopsies were obtained weekly after ABMT or on appearance of rash and were graded for GVH changes. In the first phase of this study, groups of patients received CSP dosages of either 1 mg/kg/day (7 patients), 2.5 mg/kg/day (8 patients), or 3.75 mg/kg/day (6 patients) for 28 days. Sixteen of the 21 patients (76{\%} developed cutaneous histopathologic grade 2 GVHD at a median of 34 days (range, 14-49) after ABMT, and cutaneous manifestations were present at time of positive biopsy in 11 of the 16 patients. There was no apparent difference in frequency, time to onset, or duration of GVHD among the three CSP dosage groups. In the subsequent trial, 12 patients received 1.0 mg/kg/day of CSP for 35 days; 6 developed biopsy-documented GVHD at a median of 42 days (range, 18-52) after ABMT. Overall, 22 of 33 patients (67{\%} had positive biopsies for GVHD, compared with a historical 7{\%} incidence of spontaneous GVHD in ABMT recipients. No patients had hepatic or gastrointestinal dysfunction attributable to GVHD or required specific therapy for GVHD. Six of the 33 patients died with ABMT-related complications; 3 had positive biopsies for cutaneous GVHD. Eleven patients (6 CR1, 4 CR2, 1 CR3) relapsed with AML at a median of 285 days (range, 115-633) after ABMT; 9 had positive biopsies. Sixteen patients (9 CRl, 3 CR2, 4 CR3) are alive without relapse at a median of 509+ days (range, 96+-1176+) after ABMT; 10 had cutaneous GVHD. Randomized prospective trials will be needed to determine whether autologous GVHD is associated with alterations in relapse rate and disease-free survival after ABMT for acute leukemia and lymphoma.",
keywords = "Acute myeloid leukemia, Autologous bone marrow transplantation, Cyclosporine, GVHD",
author = "Yeager, {Andrew M} and Vogelsang, {Georgia B.} and Jones, {Richard J.} and Farmer, {Evan R.} and Hess, {Allan D.} and Santos, {George W.}",
year = "1993",
doi = "10.3109/10428199309086998",
language = "English (US)",
volume = "11",
pages = "215--220",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3-4",

}

TY - JOUR

T1 - Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation for acute myeloid leukemia

AU - Yeager, Andrew M

AU - Vogelsang, Georgia B.

AU - Jones, Richard J.

AU - Farmer, Evan R.

AU - Hess, Allan D.

AU - Santos, George W.

PY - 1993

Y1 - 1993

N2 - Rodents given cyclosporhe (CSP) for several weeks after autologous or syngeneic bone marrow transplantation develop a syndrome that mimics allogeneic graft-versus-host disease (GVHD). Autologous GVHD has also been reported after administration of CSP in patients who have received autologous bone marrow transplantation (ABMT) with untreated marrow for lym-phoma or acute myeloid leukemia (AML). Our study was designed to determine whether CSP administration is associated with appearance of autologous GVHD in patients with AML receiving ABMT with 4-hydroperoxycyclophosphamide (4HC)-purged marrow and whether there was a dose-dependent effect of CSP on development of the syndrome. Thirty-three patients with AML (18 in first remission [CRl], 10 in CR2, and 5 in CR3) received intravenous CSP, beginning on the day of ABMT, after a preparative regimen of busulfan and cyclophosphamide and ABMT with 4HC-treated marrow. Skin biopsies were obtained weekly after ABMT or on appearance of rash and were graded for GVH changes. In the first phase of this study, groups of patients received CSP dosages of either 1 mg/kg/day (7 patients), 2.5 mg/kg/day (8 patients), or 3.75 mg/kg/day (6 patients) for 28 days. Sixteen of the 21 patients (76% developed cutaneous histopathologic grade 2 GVHD at a median of 34 days (range, 14-49) after ABMT, and cutaneous manifestations were present at time of positive biopsy in 11 of the 16 patients. There was no apparent difference in frequency, time to onset, or duration of GVHD among the three CSP dosage groups. In the subsequent trial, 12 patients received 1.0 mg/kg/day of CSP for 35 days; 6 developed biopsy-documented GVHD at a median of 42 days (range, 18-52) after ABMT. Overall, 22 of 33 patients (67% had positive biopsies for GVHD, compared with a historical 7% incidence of spontaneous GVHD in ABMT recipients. No patients had hepatic or gastrointestinal dysfunction attributable to GVHD or required specific therapy for GVHD. Six of the 33 patients died with ABMT-related complications; 3 had positive biopsies for cutaneous GVHD. Eleven patients (6 CR1, 4 CR2, 1 CR3) relapsed with AML at a median of 285 days (range, 115-633) after ABMT; 9 had positive biopsies. Sixteen patients (9 CRl, 3 CR2, 4 CR3) are alive without relapse at a median of 509+ days (range, 96+-1176+) after ABMT; 10 had cutaneous GVHD. Randomized prospective trials will be needed to determine whether autologous GVHD is associated with alterations in relapse rate and disease-free survival after ABMT for acute leukemia and lymphoma.

AB - Rodents given cyclosporhe (CSP) for several weeks after autologous or syngeneic bone marrow transplantation develop a syndrome that mimics allogeneic graft-versus-host disease (GVHD). Autologous GVHD has also been reported after administration of CSP in patients who have received autologous bone marrow transplantation (ABMT) with untreated marrow for lym-phoma or acute myeloid leukemia (AML). Our study was designed to determine whether CSP administration is associated with appearance of autologous GVHD in patients with AML receiving ABMT with 4-hydroperoxycyclophosphamide (4HC)-purged marrow and whether there was a dose-dependent effect of CSP on development of the syndrome. Thirty-three patients with AML (18 in first remission [CRl], 10 in CR2, and 5 in CR3) received intravenous CSP, beginning on the day of ABMT, after a preparative regimen of busulfan and cyclophosphamide and ABMT with 4HC-treated marrow. Skin biopsies were obtained weekly after ABMT or on appearance of rash and were graded for GVH changes. In the first phase of this study, groups of patients received CSP dosages of either 1 mg/kg/day (7 patients), 2.5 mg/kg/day (8 patients), or 3.75 mg/kg/day (6 patients) for 28 days. Sixteen of the 21 patients (76% developed cutaneous histopathologic grade 2 GVHD at a median of 34 days (range, 14-49) after ABMT, and cutaneous manifestations were present at time of positive biopsy in 11 of the 16 patients. There was no apparent difference in frequency, time to onset, or duration of GVHD among the three CSP dosage groups. In the subsequent trial, 12 patients received 1.0 mg/kg/day of CSP for 35 days; 6 developed biopsy-documented GVHD at a median of 42 days (range, 18-52) after ABMT. Overall, 22 of 33 patients (67% had positive biopsies for GVHD, compared with a historical 7% incidence of spontaneous GVHD in ABMT recipients. No patients had hepatic or gastrointestinal dysfunction attributable to GVHD or required specific therapy for GVHD. Six of the 33 patients died with ABMT-related complications; 3 had positive biopsies for cutaneous GVHD. Eleven patients (6 CR1, 4 CR2, 1 CR3) relapsed with AML at a median of 285 days (range, 115-633) after ABMT; 9 had positive biopsies. Sixteen patients (9 CRl, 3 CR2, 4 CR3) are alive without relapse at a median of 509+ days (range, 96+-1176+) after ABMT; 10 had cutaneous GVHD. Randomized prospective trials will be needed to determine whether autologous GVHD is associated with alterations in relapse rate and disease-free survival after ABMT for acute leukemia and lymphoma.

KW - Acute myeloid leukemia

KW - Autologous bone marrow transplantation

KW - Cyclosporine

KW - GVHD

UR - http://www.scopus.com/inward/record.url?scp=0027420487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027420487&partnerID=8YFLogxK

U2 - 10.3109/10428199309086998

DO - 10.3109/10428199309086998

M3 - Article

C2 - 8260896

AN - SCOPUS:0027420487

VL - 11

SP - 215

EP - 220

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3-4

ER -